Bulletin
Investor Alert

Topics

Hepatitis

4:15 a.m. March 17, 2021 - MarketWatch
Startup behind AstraZeneca vaccine raises millionsLONDON -- The Oxford startup behind AstraZeneca PLC's Covid-19 vaccine has raised $168 million in new funding, which it plans to use to adopt its vaccine technology for the treatment of other diseases.
2:41 p.m. March 7, 2021 - MarketWatch
IPO for Oxford COVID-19 vaccine startup in perilA startup behind the Covid-19 vaccine developed by the University of Oxford and AstraZeneca PLC is planning an initial public offering that backers hope will be the biggest market debut of an Oxford spinoff in years.
7:04 a.m. Oct. 4, 2020 - By Jaimy Lee
Abbott exec: Why better COVID-19 tests may help the U.S. get back to normal John Hackett is a longtime executive at diagnostics company Abbott In less than seven months, Abbott Laboratories has introduced six COVID-19 tests, each a little different than the last, and that’s all part of the diagnostics company’s strategy to keep improving and enhancing tests that can detect current and past infections with the novel coronavirus.
12:29 p.m. Sept. 13, 2020 - MarketWatch
AstraZeneca COVID-19 vaccine trials resumeAstraZeneca PLC said Saturday clinical trials for its experimental coronavirus vaccine have resumed in the U.K. after regulators concluded it was safe to do so, following a pause in studies globally after a person who received the vaccine had an unexplained illness.
11:23 a.m. Sept. 6, 2020 - By Quentin Fottrell
Sweden embraced herd immunity, while the U.K. abandoned the idea — so why do they both have high COVID-19 fatality rates? ‘Sweden’s prized herd immunity is nowhere in sight,’ according to an analysis in the Journal of the Royal Society of Medicine‘Sweden’s prized herd immunity is nowhere in sight,’ according to an analysis in the Journal of the Royal Society of Medicine.
12:58 a.m. Aug. 10, 2020 - By Sherri Snelling
Could flu vaccines lower your risk of Alzheimer’s? Research sheds new light Two studies released at the Alzheimer’s Association conference indicate a possible connection between flu and pneumonia shots with reducing or delaying cognitive declineThe studies show ‘vaccines are strongly associated with lower prevalence of dementia,’ says one scientist.
2:13 a.m. July 31, 2020 - By Jaimy Lee
Gilead swings to a big loss on acquisition expense, stock falls after earnings and revenue miss The drugmaker expects to produce more than 2 million courses of COVID-19 treatment remdesivir by the end of the yearShares of Gilead Sciences Inc. fell more than 1% in after-hours trading Thursday after the drugmaker reported that it swung to a large loss during the second quarter and missed estimates even after adjusting for an acquisition.
2:11 a.m. June 30, 2020 - By Jaimy Lee
Gilead’s coronavirus drug will cost $2,340 — which sounds expensive, but here’s why it’s not The drugmaker’s decision to price remdesivir below expectations could be a ‘promising sign’ of how much other COVID-19 treatments will cost, said one expertGilead Sciences Inc.’s COVID-19 drug remdesivir will cost much less than Wall Street analysts had predicted in a move that likely points to a more measured, responsible approach to the pharmaceutical pricing of treatments and vaccines during the pandemic.
10:06 a.m. June 29, 2020 - By Jaimy Lee
Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed ‘People, companies are starting to plan to make doses even before, you know, the vaccine works,’ Dr. Anthony Fauci said Tuesday on Capitol HillInovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.
9:34 a.m. May 31, 2020 - By Quentin Fottrell
‘The 1918 Spanish flu’s second wave was even more devastating’: WHO advises caution to avoid ‘immediate second peak’ Immunizations against smallpox, measles or Hepatitis B should last a lifetime, but that has not been the case for previous coronavirusesImmunizations against smallpox, measles or Hepatitis B should last a lifetime, but that has not been the case for previous coronaviruses.
10:50 a.m. May 6, 2020 - By Jaimy Lee
These 23 companies are working on coronavirus treatments or vaccines — here’s where things stand The list includes Gilead Sciences and Moderna, alongside smaller biotech companiesA mix of legacy drugmakers and small startups have stepped forward with plans to develop vaccines or treatments that target the infection caused by the novel coronavirus.
3:44 a.m. May 1, 2020 - By Jaimy Lee
Gilead expects to spend up to $1 billion on coronavirus drug this year, will donate 1.5 million vials CEO says Gilead ‘could charge for’ remdevisir, but donating entire supply through early summer ‘is the right thing to do at this time’Gilead Sciences Inc. reported better-than-expected earnings for the first quarter of the year on Thursday and detailed more of its work on remdesivir, an antiviral COVID-19 drug candidate.
8:43 a.m. April 30, 2020 - By Jaimy Lee
The pandemic has shifted focus to remdesivir, but HIV drugs will return to center stage for Gilead Gilead in the age of COVID-19: Investors will pay close attention to what the company says about what’s next for its experimental drug remdesivir, as well as its HIV portfolio and oncology ambitionsIf this pandemic is going to have a savior, investors are betting that Gilead Sciences Inc. is their personal Jesus.
5:50 a.m. April 23, 2020 - By Joseph E. Stiglitz
Should patents come before patients? How drug monopolies hamper the fight against coronavirus COVID-19 pandemic shows the urgency of replacing a monopoly-driven system with one based on cooperation and shared knowledgeDrug monopolies kill, by denying access to life-saving medicines that otherwise would have been available under an alternative system — like the one facilitating the yearly production of the flu vaccine.
Browse topics:

Filter results by

Location

Us (15)

Asia Pacific (2)

Eu (2)

Europe (2)

Africa/mideast (1)

China (1)

Link to MarketWatch's Slice.